Altimmune Inc. (ALT) Financial Statements (2024 and earlier)

Company Profile

Business Address 910 CLOPPER ROAD
GAITHERSBURG, MD 20878
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments197,815184,880190,301215,92337,24033,719
Cash and cash equivalents135,117111,097190,301115,9188,96333,719
Short-term investments62,69873,783 100,00628,277 
Restricted cash and investments4134343434634
Receivables1001734,02912,3731,6504,471
Other undisclosed current assets11,6707,7269,7621,927470548
Total current assets:209,626192,813204,126230,25739,39539,372
Noncurrent Assets
Operating lease, right-of-use asset   904698
Property, plant and equipment6511,0811,4481,0571,1041,343
Intangible assets, net (including goodwill)  12,41912,41912,82412,73213,852
Intangible assets, net (excluding goodwill)  12,41912,41912,82412,73213,852
Other noncurrent assets36361587273129184
Other undisclosed noncurrent assets      
Total noncurrent assets:1,01414,11514,73914,85814,66315,378
TOTAL ASSETS:210,640206,928218,865245,11554,05854,751
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,8028,0354,74412,0203,9234,456
Employee-related liabilities2,313   
Accounts payable2,0704,8042,03461218373
Accrued liabilities3,7323,23139611,4083,9054,083
Debt      72
Business combination, contingent consideration, liability   6,090   
Other undisclosed current liabilities6,3419,0197,442   
Total current liabilities:12,14317,05418,27612,0203,9234,527
Noncurrent Liabilities
Long-term debt and lease obligation  4,5811,4541,8281,8651,852
Long-term debt, excluding current maturities  4,5811,4541,8281,8651,852
Liabilities, other than long-term debt215  5,3902,75059
Deferred tax liabilities, net59
Other liabilities40     
Operating lease, liability175    
Business combination, contingent consideration, liability    5,3902,750 
Other undisclosed noncurrent liabilities4,183     
Total noncurrent liabilities:4,3984,5811,4547,2184,6151,911
Total liabilities:16,54121,63519,73019,2398,5386,438
Equity
Equity, attributable to parent194,099185,293199,135225,87645,52048,313
Common stock754421
Additional paid in capital665,427568,399497,342417,338187,915170,208
Accumulated other comprehensive loss(5,004)(5,227)(5,040)(5,045)(5,020)(5,040)
Accumulated deficit(466,331)(377,884)(293,171)(186,421)(137,376)(116,856)
Total equity:194,099185,293199,135225,87645,52048,313
TOTAL LIABILITIES AND EQUITY:210,640206,928218,865245,11554,05854,751

Income Statement (P&L) ($ in thousands)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues426(68)4,4108,1855,80110,331
Gross profit:426(68)4,4108,1855,80110,331
Operating expenses(96,355)(87,672)(101,324)(62,984)(27,266)(53,166)
Operating loss:(95,929)(87,740)(96,914)(54,799)(21,465)(42,834)
Nonoperating income (expense)7,4822,830(177)337886(2,487)
Investment income, nonoperating7,3512,870203323843227
Other nonoperating income (expense)166(32)(374)2415278
Interest and debt expense(35)(8)(6)(9)(2)(297)
Loss from continuing operations before equity method investments, income taxes:(88,482)(84,918)(97,096)(54,471)(20,581)(45,618)
Other undisclosed income from continuing operations before income taxes358692297
Loss from continuing operations before income taxes:(88,447)(84,910)(97,091)(54,462)(20,579)(45,321)
Income tax benefit  197 5,417596,150
Loss from continuing operations:(88,447)(84,713)(97,091)(49,044)(20,520)(39,171)
Loss before gain (loss) on sale of properties:(97,091)(49,044)(20,520)(39,171)
Other undisclosed net income      
Net loss:(88,447)(84,713)(97,091)(49,044)(20,520)(39,171)
Other undisclosed net income attributable to parent      
Net loss attributable to parent:(88,447)(84,713)(97,091)(49,044)(20,520)(39,171)
Preferred stock dividends and other adjustments     (453)(3,308)
Net loss available to common stockholders, diluted:(88,447)(84,713)(97,091)(49,044)(20,973)(42,479)

Comprehensive Income ($ in thousands)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(88,447)(84,713)(97,091)(49,044)(20,520)(39,171)
Other undisclosed comprehensive income (loss)223(187)4(24)20 
Comprehensive loss:(88,224)(84,900)(97,086)(49,069)(20,500)(39,171)
Other undisclosed comprehensive loss, net of tax, attributable to parent      (463)
Comprehensive loss, net of tax, attributable to parent:(88,224)(84,900)(97,086)(49,069)(20,500)(39,634)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: